The possibility that metoclopramide (MCP), a potent stimulator of aldosterone secretion, might influence vasopressin secretion in man was studied. MCP (10 mg, iv) increased plasma vasopressin (mean ± SD) from 1.3 ± 0.1 to 2.4 ± 0.1 pg/ml at 10 min and to 2.65± 0.1 pg/ml at 20 min (P < 0.01) in 10 recumbent normal subjects. No changes in plasma osmolality or peripheral hemodynamics, which might have accounted for the increase in vasopressin, were found. Sulpiride (100 mg iv), haloperidol (2 mg, iv), and domperidone (20 mg, iv), three chemically unrelated antidopaminergic agents, as well as TRH (200 μg, iv), failed to modify plasma vasopressin, thus suggesting that the MCP effect on vasopressin is not linked to its antidopaminergic and/or PRL-releasing properties. MCP also was effective in releasing vasopressin in 5 dehydrated subjects, in whom plasma vasopressin increased from 1.9 ± 0.2 to 3.1 ± 4 pg/ml (P < 0.05), and in 5 subjects during steady state water diuresis, in whom free water excretion decreased from 9 to 1 ml/min (P < 0.01) and plasma vasopressin increased from 0.3 ± 0.1 to 1.2 ± 0.2 pg/ml (P < 0.05). No changes in either vasopressin secretion or free water excretion occurred in 4 patients with severe central diabetes insipidus. These results suggest that MCP stimulates the release of biologically active vasopressin in man. © 1986 by The Endocrine Society.

Metoclopramide increases vasopressin secretion / G. Norbiato, M. Bevilacqua, E. Chebat, P. Bertora, P. Cavaiani, C. Baruto, S. Fumagalli, U. Raggi. - In: THE JOURNAL OF CLINICAL ENDOCRINOLOGY AND METABOLISM. - ISSN 0021-972X. - 63:3(1986), pp. 747-750.

Metoclopramide increases vasopressin secretion

P. Bertora;
1986

Abstract

The possibility that metoclopramide (MCP), a potent stimulator of aldosterone secretion, might influence vasopressin secretion in man was studied. MCP (10 mg, iv) increased plasma vasopressin (mean ± SD) from 1.3 ± 0.1 to 2.4 ± 0.1 pg/ml at 10 min and to 2.65± 0.1 pg/ml at 20 min (P < 0.01) in 10 recumbent normal subjects. No changes in plasma osmolality or peripheral hemodynamics, which might have accounted for the increase in vasopressin, were found. Sulpiride (100 mg iv), haloperidol (2 mg, iv), and domperidone (20 mg, iv), three chemically unrelated antidopaminergic agents, as well as TRH (200 μg, iv), failed to modify plasma vasopressin, thus suggesting that the MCP effect on vasopressin is not linked to its antidopaminergic and/or PRL-releasing properties. MCP also was effective in releasing vasopressin in 5 dehydrated subjects, in whom plasma vasopressin increased from 1.9 ± 0.2 to 3.1 ± 4 pg/ml (P < 0.05), and in 5 subjects during steady state water diuresis, in whom free water excretion decreased from 9 to 1 ml/min (P < 0.01) and plasma vasopressin increased from 0.3 ± 0.1 to 1.2 ± 0.2 pg/ml (P < 0.05). No changes in either vasopressin secretion or free water excretion occurred in 4 patients with severe central diabetes insipidus. These results suggest that MCP stimulates the release of biologically active vasopressin in man. © 1986 by The Endocrine Society.
Settore MED/13 - Endocrinologia
Article (author)
File in questo prodotto:
Non ci sono file associati a questo prodotto.
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/852187
Citazioni
  • ???jsp.display-item.citation.pmc??? 2
  • Scopus 31
  • ???jsp.display-item.citation.isi??? 36
social impact